Great news! Today ResearchersAgainstAlzheimer’s published an exciting new report that concludes that 17 drugs in current phase-3 clinical trials may launch in the next 5 years. This unprecedented advance in Alzheimer’s research follows more than a decade of negative drug trials and poor funding for Alzheimer's research, and it certainly provides much-needed hope for people living with Alzheimer's disease, their care partners, and those at risk of developing the disease.
UsAgainstAlzheimer's co-founder George Vradenburg notes that "our mission is to stop Alzheimer's by 2020. Our work has focused on disrupting business as usual by increasing research resources, speeding drug development, and assuring access of innovative medicines to those with or at risk of the disease. Should drugs in late-stage development prove successful, insurers and physicians will need to step up their game."
To learn more, visit UsAgainstAlzheimer's.